The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

February 22, 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale and primary endpoints of the BEACON CRC study in BRAF V600E–mutant metastatic colorectal cancer.

February 22, 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the safety profile of veliparib examined in the VELIA trial looking at patients with high-grade serous ovarian cancer.

February 14, 2020

Prithviraj Bose, MD, discusses treatment for patients with progressive myelofibrosis.

February 13, 2020

Treatment with a CD19-targeted CAR-natural killer–cell therapy led to a 73% objective response rate, including 7 complete responses, in patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia.

February 12, 2020

The presence of circulating tumor cell was found to be independently associated with relapse in patients with stage III melanoma, suggesting that CTC assessment may be useful in identify patients who are at risk for relapse and could benefit from adjuvant therapy.

February 07, 2020

Courtney DiNardo, MD, MSCE, discusses the rationale to combine enasidenib (Idhifa) with azacitidine in acute myeloid leukemia.

February 05, 2020

James M. Reuben, PhD, MBA, discusses the search for biomarkers in patients with metastatic breast cancer.

February 04, 2020

James M. Reuben, PhD, MBA, discusses his research on using liquid biopsies to identify predictive biomarkers for immunotherapy in patients with metastatic breast cancer.

February 01, 2020

Naoto Ueno, MD, PhD, FACP, discusses residual cancer burden and immunotherapy in inflammatory breast cancer.

January 29, 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.

January 28, 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the VELIA trial and the impact the results are going to have on the use of PARP inhibitors in ovarian cancer.

January 21, 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the implications of the phase III VELIA trial in ovarian cancer.

January 21, 2020

Michael A. Choti, MD, discusses the future of treatment for patients with stage IV pancreatic cancer.

January 21, 2020

Michael Wang, MD, discusses the results of the phase II ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

January 17, 2020

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

January 13, 2020

Robert L. Coleman, MD, discusses the next steps of treatment for patients with high-grade serous ovarian cancer.

January 06, 2020

Michael Wang, MD, discusses the benefit of BTK inhibitors in mantle cell lymphoma.

December 23, 2019

Michael Wang, MD, discusses the ZUMA-2 trial and the potential impact of CAR T-cell therapy on the treatment paradigm in mantle cell lymphoma.

December 14, 2019

Jennifer McQuade, MD, MS, MA, LAc, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.

December 13, 2019

Pavlos Msaouel, MD, PhD, discusses the rationale for a phase II study evaluating sitravatinib in combination with nivolumab in patients with metastatic or advanced urothelial cancer.